Welcome to our dedicated page for Fractyl Health news (Ticker: GUTS), a resource for investors and traders seeking the latest updates and insights on Fractyl Health stock.
Fractyl Health (NASDAQ: GUTS) is a clinical-stage biotechnology company developing novel therapies targeting the root causes of obesity and type 2 diabetes. This page provides investors and healthcare professionals with timely updates on the company’s progress, including clinical trial results, regulatory milestones, and strategic initiatives.
Key resources include: Press releases detailing advancements in the Revita® duodenal resurfacing procedure, updates on the Rejuva® gene therapy platform, and analyses of pivotal studies like REMAIN-1. Track FDA designations, partnership announcements, and scientific publications demonstrating the company’s unique approach to metabolic disease modification.
All content is rigorously sourced from official company communications and regulatory filings. Bookmark this page to stay informed about Fractyl Health’s progress in developing durable alternatives to chronic medications through its innovative procedural and gene therapy platforms.
Fractyl Health, Inc. presented promising 6-month follow-up data from its German real-world registry study of Revita for advanced Type 2 Diabetes (T2D). Participants showed sustained improvements in blood glucose, weight loss, and reduced T2D medication use after a single treatment. No serious adverse events related to the device or procedure have been reported. These results indicate the potential of Revita for durable weight loss maintenance.
Fractyl Health, Inc. (Nasdaq: GUTS) will present at BofA Securities 2024 Health Care Conference. Dr. Harith Rajagopalan, CEO, will participate in a fireside chat on May 15, 2024. The Company focuses on innovative treatments for obesity and type 2 diabetes.
Fractyl Health, Inc. (Nasdaq: GUTS) will report Q1 2024 financial results and business updates on May 13, 2024. The company focuses on metabolic therapeutics for obesity and T2D, hosting a conference call at 4:30 p.m. ET.
Fractyl Health, Inc. (Nasdaq: GUTS) will present new data at the German Diabetes Association (DDG) Annual Meeting on its real-world registry study of Revita for T2D and at the Digestive Disease Week (DDW) on the potential of Rejuva in reducing liver fat. The presentations include clinical updates and preclinical data demonstrating the effectiveness of their metabolic therapeutics in treating obesity and T2D.
FAQ
What is the current stock price of Fractyl Health (GUTS)?
What is the market cap of Fractyl Health (GUTS)?
